Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.36 |
| ▸ | BHMT | Q93088 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18762462 | 0.90 | SLC1A2 (0.43) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL7376089 | 0.90 | SLC1A2 (0.43) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL12189727 | 0.90 | SLC1A2 (0.43) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| Hydrochloric Acid SCHEMBL6934105 | 0.88 | SLC1A2 (0.42) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| Trifluoroacetic Acid SCHEMBL18762609 | 0.85 | GRB2 (0.39) | GRB2SLC1A2SLC1A1SLC1A3PTPN1 | |
| Trifluoroacetic Acid SCHEMBL4576488 | 0.82 | GRB2 (0.42) | GRB2SLC1A2SLC1A1SLC1A3PTPN1 | |
| Trifluoroacetic Acid SCHEMBL27695113 | 0.82 | GRB2 (0.42) | GRB2SLC1A2SLC1A1SLC1A3PTPN1 | |
| SCHEMBL18775025 | 0.79 | SLC7A5 (0.40) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL18774911 | 0.76 | SLC7A5 (0.41) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 | |
| SCHEMBL18762498 | 0.76 | SLC7A5 (0.41) | SLC1A2SLC1A1SLC1A3SLC7A5GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1345931-A2 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002040462-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2002-05-23 | — | — | WO | disclosed |
| EP-1178986-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | Medivir UK Ltd (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069855-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | GRB2 1518/4885SLC1A2 4253/4885SLC1A1 3823/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | GRB2 1956/4885SLC1A2 4246/4885SLC1A1 3418/4885 |
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | GRB2 2086/4885SLC1A2 4493/4885SLC1A1 4372/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | GRB2 702/4885SLC1A2 3340/4885SLC1A1 2676/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | GRB2 2086/4885SLC1A2 4493/4885SLC1A1 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.